OBJECTIVE：To evaluate the clinical efficacy and safety of icotinib in the treatment of advanced non-small cell lung cancer （NSCLC）， andprovide evidence-based reference for clinic. METHODS：Retrieved from PubMed， EMBase， Cochrane Library， CBM， CJFD and Wanfang database， randomized controlled trials （RCT） about icotinib（test group） versus gefitinib or erlotinib （control group）in the treatment of advanced NSCLC. Meta-analysis was performed by using Rev Man 5.0 software after data extractions and quality evaluation with Cochrane 5.1.0 systematic review manuals. RESULTS： Totally 5 RCT were enrolled， involving 513 patients. Results of Meta-analysis showed there were no significant differences in the total effective rate [OR＝1.19，95％CI（0.79，1.78），P＝0.40]， the disease control rate[OR＝1.01，95％CI（0.69，1.50），P＝0.94] and the incidence of diarrhea [OR＝0.68，95％CI（0.45，1.03），P＝0.07] between 2 groups； the incidence of rash in test group was significantly lower than control group， the difference was statistically significant [OR＝0.69，95％CI（0.48，0.99），P＝0.04]. CONCLUSIONS： The clinical efficacy of icotinib versus gefitinib or erlotinib in the treatment of NSCLC is equivalent， but it can reduce the incidence of rash.